Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4004869 | 0.88 | AR (0.53) | ARPGR | |
| SCHEMBL14988916 | 0.84 | AR (0.53) | ARPGR | |
| SCHEMBL2058701 | 0.82 | AR (0.52) | ARPGR | |
| SCHEMBL14988933 | 0.80 | AR (0.51) | AR | |
| SCHEMBL14989012 | 0.76 | AR (0.44) | AR | |
| SCHEMBL1291496 | 0.76 | AR (0.53) | ARPGR | |
| SCHEMBL1291575 | 0.76 | AR (0.53) | ARPGR | |
| SCHEMBL14988926 | 0.75 | AR (0.49) | ARPGR | |
| SCHEMBL16845623 | 0.75 | AR (0.67) | ARPGR | |
| Acetic Acid SCHEMBL7784177 | 0.74 | AR (0.89) | ARPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1791821-B1 | NOVEL IMIDAZOLIDIN-2-ONE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2013-06-05 | — | — | EP | claimed |
| US-7531565-B2 | Imidazolidin-2-one derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-05-12 | — | — | US | claimed |
| EP-1791821-A2 | NOVEL IMIDAZOLIDIN-2-ONE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-06 | — | — | EP | claimed |
| US-20060063819-A1 | Novel imidazolidin-2-one derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-23 | — | — | US | claimed |
| WO-2006031715-A2 | NOVEL IMIDAZOLIDIN-2-ONE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063819-A1 | Novel imidazolidin-2-one derivatives as selective androgen receptor modulators (SARMS) | AR, NR5A1, NR5A2 | AR 1/4885PGR 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.